Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics.
about
Incorporating genetics and genomics in risk assessment for inhaled manganese: from data to policyConsiderations for using genetic and epigenetic information in occupational health risk assessment and standard settingCancer pharmacogenomics: strategies and challengesFood-induced brain responses and eating behaviourHuman pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activityEpigenome-Wide Association Studies (EWAS) in CancerSIFORM: shared informative factor models for integration of multi-platform bioinformatic data.A Preliminary Examination of Thought Suppression, Emotion Regulation, and Coping in a Trauma Exposed Sample.Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Integrating diverse genomic data using gene setsPharmacogenomics of mood stabilizers in the treatment of bipolar disorder.Applications of pharmacogenetics in psychiatry: personalisation of treatment.Dopamine receptor polymorphisms and drug response in schizophrenia.Selection of extreme phenotypes: the role of clinical observation in translational research.Improved drug therapy: triangulating phenomics with genomics and metabolomics.Advancing the medical management of epilepsy: disease modification and pharmacogenetics.Structural and functional bases of inhibited temperamentExpectation and temperament moderate amygdala and dorsal anterior cingulate cortex responses to fear faces.UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.Neurocircuitry underlying risk and resilience to social anxiety disorderGenome-wide association study of warfarin maintenance dose in a Brazilian sampleCommon VDR polymorphisms and idiopathic short stature in children from northern Greece.A non-synonymous single nucleotide polymorphism in an OPRM1 splice variant is associated with fentanyl-induced emesis in women undergoing minor gynaecological surgeryDINGO: differential network analysis in genomicsPharmacogenomics of warfarin in populations of African descent.An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locusThe retinoic acid receptor alpha (RARA) gene is not associated with myopia, hypermetropia, and ocular biometric measures.Prenatal pulmonary hypertension index: novel prenatal predictor of severe postnatal pulmonary artery hypertension in antenatally diagnosed congenital diaphragmatic herniaHead-and-neck squamous cell carcinoma risk in smokers: no association detected between phenotype and AHR, CYP1A1, CYP1A2, or CYP1B1 genotype.Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.Pharmacogenetics of coumarin anticoagulants in Brazilians.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Identification of coagulation gene 3'UTR variants that are potentially regulated by microRNAs.Altered Prefrontal Cortex Function Marks Heightened Anxiety Risk in Children.MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.Prediction of drug response and safety in clinical practice.The future of the human SNP identification: which individuals to sequence?Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
P2860
Q23911116-BE11B37A-8FE9-462E-BD91-90F95CD72F42Q23919015-5BC05D8E-E8CE-47BA-8CD7-6003D9BE9E4FQ24289309-CF29AA48-316C-42C8-A51E-618FBDBC55BFQ27010333-FB7E5D88-4948-4807-B024-DE25C6556BE2Q28269219-438D9B4A-4930-4800-A702-74C787F9A4E5Q28310536-8A92007F-597A-4C2C-AD24-293F839E7C72Q31112697-1C751B7E-2866-4769-B9CC-944136AE1C3EQ33567094-4047BA34-4701-40A0-A4D7-5F27E6DEC82BQ33770184-0C385F44-9098-42A1-BF28-C46F9CEFBDDAQ34054123-16377C70-F0AB-45DB-B14F-4A6BB57AE0FAQ34146222-5FF45EA8-5266-4876-8C5F-C512F2314754Q34240923-51AF0F41-897A-4C6B-9C22-AFAEB7EEBB04Q34355260-2D6B6105-CFAB-4FE9-903F-1BAE1F040B77Q34384968-AAEFECBB-C6FD-4B04-870D-80B239A63311Q34436487-4D2C7408-6705-4975-929F-958F3E4D6936Q34579490-B7F36943-F765-4C36-8712-BA485CB11FE7Q34597302-6602037A-F951-4315-B760-C1E4F9D2DD19Q34629740-80D78CB0-25AD-4BEA-9D3D-6F5B0F9FB2A8Q34947658-B05C5F69-5ED8-404C-A78D-A0D0B020F6D5Q35000912-E403FB85-894E-42E3-A6C8-BCEC4265C2D6Q35038903-C917C7FA-EBF7-4D93-A18F-1DB4CDE64F88Q36068687-49759DB8-5B5F-47F2-A74A-4D3BA97D9887Q36071948-074DD1D1-87DB-4164-98B8-5445F9F7A59AQ36380880-12308CF5-A543-4FB4-9854-247EE5082DB8Q36573647-38FF7ABC-21AA-4BFB-8207-8117B0321286Q36629209-E060E5F0-8EE2-4BF3-A81C-1DAD822D0844Q36693352-B3D8D507-83F4-44A0-AB3B-AA7C8B0FCA35Q37269817-83524649-7B0A-4619-8BEF-152600E0F913Q37409853-34DA1B7B-3A67-4D1A-A00D-60B85DEC6DC3Q37450305-88B8A241-C981-4461-8FA8-605E92EE64F3Q37514211-48405949-0992-4FFC-8CC5-F274494793ADQ38262829-6F4D0312-0C43-4D85-879A-53AE37B1BED7Q38513661-9ACE3B39-237E-40EF-8A66-F7B20F8F2481Q40227354-8B54AF11-B730-4BAC-A092-9D5977D941ABQ40966807-91E3D787-2357-41C0-A20D-C8BD86D9DE37Q42317002-4ED4D79D-E775-412C-8F7C-F4DEA30104D6Q42870458-BADD0EA0-138D-47EA-8F31-25084B8AC0B1Q43125931-3F55A5B2-A994-4C3A-B728-921F05643D28Q43150810-999A3CEF-663E-4CD3-BA49-ADB06B3E7B6AQ43460357-631EE574-0A20-400A-A83F-57A391B66EE5
P2860
Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@ast
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@en
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@nl
type
label
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@ast
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@en
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@nl
prefLabel
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@ast
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@en
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@nl
P1476
Extreme discordant phenotype m ...... to clinical pharmacogenetics.
@en
P2093
P304
P356
10.1016/S0014-2999(00)00809-8
P407
P577
2000-12-01T00:00:00Z